2. Search Result
Search Result
Results for "

1c

" in MedChemExpress (MCE) Product Catalog:

381

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

2

Biochemical Assay Reagents

21

Peptides

6

Inhibitory Antibodies

20

Natural
Products

127

Recombinant Proteins

62

Isotope-Labeled Compounds

122

Antibodies

8

Click Chemistry

62

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139598
    LFHP-1c
    1 Publications Verification

    		 Phospholipase Cardiovascular Disease
    LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection [1].
    LFHP-1c
  • HY-P99362
    Ensituximab

    Anti-MUC5AC Reference Antibody (ensituximab); NEO-102

    		 Mucin Cancer
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer [1] .
    Ensituximab
  • HY-17429
    Flecainide acetate
    2 Publications Verification

    R-818

    		 Sodium Channel Cardiovascular Disease
    Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
    Flecainide acetate
  • HY-N13953
    Pyralomicin 1c

    		Antibiotic Bacterial Infection
    Pyralomicin 1c is an antibiotic with antibacterial activity [1].
    Pyralomicin 1c
  • HY-N11537
    2-Methoxy-6-pentadecyl-1,4-benzoquinone

    		Others Others
    2-Methoxy-6-pentadecyl-1,4-benzoquinone (1c) is a pentadecyl derivative that can be isolated from seed oils of different iris plants such as I. pseudacorus, I. missouriensis and I. sibirica [1].
    2-Methoxy-6-pentadecyl-1,4-benzoquinone
  • HY-U00374
    Sch59498

    		Phosphodiesterase (PDE) Neurological Disease
    Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c).
    Sch59498
  • HY-N11583
    Jasmololone

    Jasmololon

    		 Others Others
    Jasmololone (compound 1c) is a reduced compound that can be oxidized by manganese dioxide to form the corresponding diketone [1].
    Jasmololone
  • HY-163619
    Anticancer agent 227

    		Apoptosis Mitophagy Cancer
    Anticancer agent 227 (compound YNU-1c) is a potent anticancer agent. Anticancer agent 227 shows antiproliferative activity. Anticancer agent 227 induces apoptosis and mitophagy [1].
    Anticancer agent 227
  • HY-147931
    Human enteropeptidase-IN-2

    		Enteropeptidase Metabolic Disease
    Human enteropeptidase-IN-2 (compound 1c) is a highly potent enteropeptidase inhibitor. Human enteropeptidase-IN-2 can be used for anti-obesity research [1].
    Human enteropeptidase-IN-2
  • HY-111049
    GSK8062

    		FXR Metabolic Disease
    GSK8062 is a farnesoid X receptor (FXR) agonist with activity that improves compound development parameters. Analog 1c of GSK8062 showed a reduction in weight gain and serum glucose levels [1].
    GSK8062
  • HY-148087
    AZD5462
    1 Publications Verification

    		 RXFP Receptor Cardiovascular Disease
    AZD5462 is a RXFP1 modulator, can be used for heart failure research. RXFP1 is the cognate receptor for human relaxin, belongs to GPCR family 1c number with anti-fibrotic and anti-inflammatory properties [1].
    AZD5462
  • HY-100980
    HEAT hydrochloride

    BE2254 hydrochloride

    		 Adrenergic Receptor Neurological Disease Cancer
    HEAT (BE2254) hydrochloride is a selective alpha 1 adrenergic receptor antagonist. HEAT hydrochloride, a phenethylamine derivative, shows pKis of 9, 9.1, and 8.57 for alpha 1a, alpha 1b and alpha 1c, respectively [1] .
    HEAT hydrochloride
  • HY-163674
    Mincle agonist 1

    		Interleukin Related Inflammation/Immunology
    Mincle agonist 1 (compound 1c) is a Mincle agonist. Mincle agonist 1 can promote IL-1β expression in BMDM cells. Mincle agonist 1 can be used in immune and inflammation related research [1].
    Mincle agonist 1
  • HY-148326
    Glu(OtBu)-Val-Cit-PAB-OH

    		ADC Linker Others
    Glu(OtBu)-Val-Cit-PAB-OH (compound L5-1c) is an non-cleavable ADC linker. Glu(OtBu)-Val-Cit-PAB-OH has been used to synthesis protein-tubulysin conjugates [1].
    Glu(OtBu)-Val-Cit-PAB-OH
  • HY-149900
    Antiviral agent 33

    		Biochemical Assay Reagents Infection
    Antiviral agent 33 (compound 1c) is a double-stranded DNA (dsDNA) virus inhibitor with IC50 values of 0.0790 and 0.1572 µM for VACV and AdV5, respectively. Antiviral agent 33 also has potential for oral administration [1].
    Antiviral agent 33
  • HY-169159
    SIRT6 activator 2

    		Sirtuin Metabolic Disease
    SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases [1].
    SIRT6 activator 2
  • HY-113567
    GSK2324

    		FXR Metabolic Disease
    GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively [1].
    GSK2324
  • HY-P99614
    Fazpilodemab

    BFKB8488A; RG-7992; RO-7040551

    		 FGFR Metabolic Disease
    Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) [1].
    Fazpilodemab
  • HY-B0061
    Tandospirone citrate
    2 Publications Verification

    SM-3997 citrate

    		 5-HT Receptor Neurological Disease
    Tandospirone citrate is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over SR-2, SR-1C, α1, α2, D1 and D2 receptors (Ki values ranging from 1300-41000 nM).
    Tandospirone citrate
  • HY-143768
    Cap-dependent endonuclease-IN-14

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) [1].
    Cap-dependent endonuclease-IN-14
  • HY-N1967
    Dihydrocurcumin

    		Fatty Acid Synthase (FASN) Metabolic Disease
    Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways [1].
    Dihydrocurcumin
  • HY-17429S
    Flecainide-d4 acetate

    R-818-d4

    		 Sodium Channel Cardiovascular Disease
    Flecainide-d4 (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential [1] .
    Flecainide-d4 acetate
  • HY-17429R
    Flecainide acetate (Standard)

    R-818 (Standard)

    		 Reference Standards Sodium Channel Cardiovascular Disease
    Flecainide (acetate) (Standard) is the analytical standard of Flecainide (acetate). This product is intended for research and analytical applications. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
    Flecainide acetate (Standard)
  • HY-123402
    GSK3987
    1 Publications Verification

    		 LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation [1].
    GSK3987
  • HY-162826
    Apoptosis inducer 27

    		Apoptosis Cancer
    Apoptosis inducer 27 (compound 1c) is a potent inhibitor of MDA-MB-231 breast cancer (IC50: 12.8 μM) and can induce early apoptosis in breast cancer cells. Apoptosis inducer 27 can bind to DNA molecules, Bax and Bcl-2 proteins, and induce DNA damage [1].
    Apoptosis inducer 27
  • HY-19806A
    Ceftolozane sulfate
    1 Publications Verification

    CXA-101; FR264205

    		 Bacterial Infection
    Ceftolozane (CXA-101) sulfate is an antipseudomonal cephalosporin. Ceftolozane binds to P. aeruginosa essential PBPs (1b, 1c, 2 and 3) with high affinity. Ceftolozane inhibits cell wall synthesis by binding the PBPs. Ceftolozane sulfate inhibits P. aeruginosa and Enterobacteriaceae [1] .
    Ceftolozane sulfate
  • HY-146495
    Antitubercular agent-19

    		Bacterial Infection
    Antitubercular agent-19 (Compound 1c) is an antitubercular agent. Antitubercular agent-19 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-19 shows low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice [1].
    Antitubercular agent-19
  • HY-111820
    CK1-IN-1

    		Casein Kinase p38 MAPK Cardiovascular Disease
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis [1].
    CK1-IN-1
  • HY-155124
    Antiproliferative agent-32

    		Apoptosis Cancer
    Antiproliferative agent-32 (Compound 1c) inhibits the phosphorylation of PI3K/Akt/mTOR signaling pathway. Antiproliferative agent-32 inhibits Huh7 and SK-Hep-1 cells proliferation, and induce cells apoptosis, causes mitochondrial damage. Antiproliferative agent-32 can be used for research of hepatocellular carcinoma [1].
    Antiproliferative agent-32
  • HY-163844
    PD-1/PD-L1-IN-49

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC50 of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint [1].
    PD-1/PD-L1-IN-49
  • HY-136569
    DSR-141562

    		Phosphodiesterase (PDE) Neurological Disease
    DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia [1] .
    DSR-141562
  • HY-173187
    Keap1-Nrf2-IN-27

    		Keap1-Nrf2 Inflammation/Immunology
    Keap1-Nrf2-IN-27 (compound 1C) is a inhibitor of Keap1-Nrf2 protein-protein interaction (PPI) with KD2 value of 0.119 μM. Keap1-Nrf2-IN-27 suppresses the expression of pro-inflammatory cytokine TNF-α and IL-6 in the LPS-induced RAW264.7 cell model [1].
    Keap1-Nrf2-IN-27
  • HY-174272
    GSK-3β inhibitor 27

    		GSK-3 Amyloid-β Neurological Disease
    GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC50 value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) [1].
    GSK-3β inhibitor 27
  • HY-Y0319G
    Magnesium acetate tetrahydrate
    2 Publications Verification

    		 Endogenous Metabolite AMPK Reactive Oxygen Species (ROS) Caspase Fungal PPAR Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Magnesium acetate tetrahydrate is a carboxylic acid and short-chain fatty acid (SCFAs). Magnesium acetate tetrahydrate activates AMPK, increases ROS, cleaved caspase 9, PPARα, downregulates SREBP-1c, ChREBP expression. Magnesium acetate tetrahydrate exhibits antifungal activity against Saccharomyces cerevisiae W303-1A. Magnesium acetate tetrahydrate regulates energy metabolism. Magnesium acetate tetrahydrate has anticancer activity against gastric cancer. Magnesium acetate tetrahydrate induces writhing reaction and ulcerative colitis. Magnesium acetate tetrahydrate can be used in the researches for gastric cancer, ulcerative colitis, hepatic steatosis, and pain [1] .
    Magnesium acetate tetrahydrate
  • HY-N0853
    Alisol A
    4 Publications Verification

    		 AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity [1] .
    Alisol A
  • HY-W015924
    2-Hydroxyisobutyric acid

    		Endogenous Metabolite Metabolic Disease
    2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
    2-Hydroxyisobutyric acid
  • HY-174133
    HSD17B13-IN-104

    		17β-HSD Metabolic Disease Inflammation/Immunology
    HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective HSD17B13 inhibitor (IC50=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis [1].
    HSD17B13-IN-104
  • HY-W015924R
    2-Hydroxyisobutyric acid (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
    2-Hydroxyisobutyric acid (Standard)
  • HY-N0853R
    Alisol A (Standard)

    		Reference Standards AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related Infection Cardiovascular Disease Metabolic Disease Cancer
    Alisol A (Standard) is the analytical standard of Alisol A (HY-N0853). This product is intended for research and analytical applications. Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity [1] .
    Alisol A (Standard)
  • HY-173132
    AKR1Cs-IN-1

    		Aldose Reductase Cancer
    AKR1Cs-IN-1 (Compound 29) is a potent and broad-spectrum inhibitor targeting members of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). By simultaneously occupying the SP2 and SP3 pockets, it effectively inhibits multiple isoforms and disrupts metabolic pathways associated with drug resistance. In enzymatic activity assays, AKR1Cs-IN-1 exhibited significant inhibitory potency, with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM against AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. In the doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, AKR1Cs-IN-1 showed remarkable resensitization effects and significantly enhanced the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on overcoming drug resistance in breast cancer [1].
    AKR1Cs-IN-1
  • HY-160267
    iPAF1C

    		DNA/RNA Synthesis HIV Infection
    iPAF1C is a potent inhibitor of polymerase-associated factor 1 complex (PAF1C). iPAF1C has anti-HIV activity [1].
    iPAF1C
  • HY-P3418
    CKLF1-C27

    		CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research [1].
    CKLF1-C27
  • HY-P3982
    CKLF1-C19

    		CCR Inflammation/Immunology
    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 [1].
    CKLF1-C19
  • HY-P3418A
    CKLF1-C27 TFA

    		CCR ERK Inflammation/Immunology
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research [1].
    CKLF1-C27 TFA
  • HY-163610
    AKR1C3-IN-13

    		Ligands for Target Protein for PROTAC Aldose Reductase Cancer
    AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells [1].
    AKR1C3-IN-13
  • HY-157810
    AKR1C3-IN-11

    		Aldose Reductase Cancer
    AKR1C3-IN-11 (Compound 6e) is a Aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 2.0 μM. AKR1C3-IN-11 inhibit cell proliferation in combination with abiraterone (HY-70013). AKR1C3-IN-11 can be used for the research of prostate cancer [1].
    AKR1C3-IN-11
  • HY-146573
    AKR1C3-IN-6

    		Aldose Reductase 17β-HSD Cancer
    AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC50 values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity [1].
    AKR1C3-IN-6
  • HY-163323
    AKR1C3-IN-12

    		Aldose Reductase Cancer
    AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer [1].
    AKR1C3-IN-12
  • HY-P10655
    Caloxin 1C2

    		Proton Pump Calcium Channel Cardiovascular Disease
    Caloxin 1C2 is a specific PMCA (plasma-membrane Ca 2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca 2+ transfer. Caloxin 1C2 affects coronary contractility [1] .
    Caloxin 1C2
  • HY-138557
    AKR1C3-IN-4

    		17β-HSD Cancer
    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research [1].
    AKR1C3-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: